543500 Stock Overview
Engages in the marketing, trading, and distribution of pharmaceutical formulations in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Evoq Remedies Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2.50 |
| 52 Week High | ₹12.70 |
| 52 Week Low | ₹2.11 |
| Beta | 0.52 |
| 1 Month Change | -63.77% |
| 3 Month Change | -68.27% |
| 1 Year Change | -75.15% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -89.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 543500 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.7% | 6.8% | 5.7% |
| 1Y | -75.1% | 16.3% | 4.2% |
Return vs Industry: 543500 underperformed the Indian Pharmaceuticals industry which returned 16.3% over the past year.
Return vs Market: 543500 underperformed the Indian Market which returned 4.2% over the past year.
Price Volatility
| 543500 volatility | |
|---|---|
| 543500 Average Weekly Movement | 13.9% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in IN Market | 9.5% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: 543500's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 543500's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Bhumishth Patel | www.evoqremedies.com |
Evoq Remedies Limited engages in the marketing, trading, and distribution of pharmaceutical formulations in India. The company trades in sweeteners, such as acesulfame potassium, aspartem, dextrose, erythritol, euro vanillin powder, malodextrin, miglitol, etc.; amino acids, such as L- alanine, L-arginine, L-aspartic acid, L-carnitine, L-cystine, L-glutamic acids, L-glutamine, L-glutathione, L-glycine, L-isoleucine, LL-trytophan, L-tyrosine, L-lysine, N-acetyl, and L-andystine; excipients, which include aspartem, bronopol, cross carmellous sodium, cross povidone, ethyl olliate, hard peraffin, hpmc all grades, light liquid paraffin, mannitol, menthol crystal, etc.; neutraceuticals; and opthalamics, which include atropine sulphate, bimatoprost, brimonidine, bromfenac, cyclopentolate, dorzolamide fluoromethelone, flurbiprofen, gatifloxacin, ketorolac tromethamine, latanoprost, natamycin, nepafenac, olopatadine, sulphacetamide sodium, timolol meleate, etc. It also offers ointments, such as adapalene, allantoin, avobenzone, azealic acid, calamine, chlorocresol, cetrimide, clindamycin phoshphate, clobetasol propionate, clotrimazole, cream base, cyclosporine, fluocinolol acetonide, fusidic acid, gamabenzene, gentamycin sulphate, halobetasol, hydroquinone, etc.; and oncology drugs, such as abiraterone acetate, alfuzosin, anastrazole, axitinib, azacitidine, bicalutamide, bleomycin, bosutinib, busualphan, capcitabine, carboplatin, cisplatin, etc. It also offers anti-biotic drugs, anti-malarial drugs, anti-allergic, anti cold drugs, analgesic/ anti-pyretic, anti inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastro intestinal drugs, steroids, gynecology drugs, calcium, multivitamins, anti-oxidants, and injections. In addition, it provides vitamins, dairy and spice products, sterile, active pharmaceutical ingredients, and veterinary feed products.
Evoq Remedies Limited Fundamentals Summary
| 543500 fundamental statistics | |
|---|---|
| Market cap | ₹62.25m |
| Earnings (TTM) | -₹12.22m |
| Revenue (TTM) | ₹24.17m |
2.6x
P/S Ratio-5.1x
P/E RatioIs 543500 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 543500 income statement (TTM) | |
|---|---|
| Revenue | ₹24.17m |
| Cost of Revenue | ₹8.29m |
| Gross Profit | ₹15.88m |
| Other Expenses | ₹28.10m |
| Earnings | -₹12.22m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 65.70% |
| Net Profit Margin | -50.56% |
| Debt/Equity Ratio | 6.5% |
How did 543500 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/22 11:41 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Evoq Remedies Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.